ARVINAS, INC. ARVN
We are a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through our PROteolysis TArgeting Chimera, or PROTAC, protein degradation platform, we are pioneering the development of a new class of therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. We have designed and optimized our proprietary PROTAC Discovery Engine for the discovery of PROTAC therapeutics to address diseases caused by abnormal proteins or aberrant protein expression. We believe that our targeted protein degradation approach is a novel therapeutic modality that may provide distinct advantages over existing therapies and address a broad range of targets, including historically undruggable proteins, in areas of significant unmet need.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $262.6M | $263.4M | $78.5M | $131.4M | $53.6M | $25.9M | $43.0M | $14.3M | $7.6M | — |
| R&D | $285.2M | $348.2M | $379.7M | $315.0M | $180.4M | $108.4M | $67.2M | $45.2M | $28.8M | — |
| SG&A | $95.9M | $165.4M | $100.3M | $79.6M | $61.6M | $38.3M | $27.3M | $12.9M | $3.5M | — |
| Total operating expenses | $381.1M | $513.6M | $480.0M | $394.6M | $242.0M | $146.7M | $94.5M | $58.1M | $32.3M | — |
| Operating income | -$118.5M | -$250.2M | -$401.5M | -$263.2M | -$188.4M | -$120.8M | -$51.5M | -$43.8M | -$24.8M | — |
| Interest expense | — | $0 | $0 | $0 | $0 | $100.0K | $100.0K | $57.4K | $50.4K | — |
| Pre-tax income | -$80.5M | -$198.3M | -$363.9M | -$251.0M | -$184.1M | -$115.2M | -$70.3M | -$41.5M | -$24.0M | — |
| Income tax | $300.0K | $600.0K | $900.0K | $20.9M | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$81.0M | -$199.0M | -$367.0M | -$283.0M | -$191.0M | -$119.3M | -$70.3M | -$41.5M | -$24.0M | — |
| EPS, basic | -1.14 | -2.77 | -6.62 | -5.31 | -3.82 | -3.02 | -2.13 | — | — | — |
| EPS, diluted | -1.14 | -2.77 | -6.62 | -5.31 | -3.82 | -3.02 | -2.13 | -25.45 | -15.08 | — |
| Shares, diluted (wtd. avg.) | 70.9M | 71.9M | 55.5M | 53.2M | 50.0M | 39.5M | 32.9M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $142.9M | $100.5M | $311.7M | $86.8M | $112.8M | $588.4M | $9.2M | $3.2M | $30.9M | $5.1M |
| Short-term investments | $542.5M | $938.9M | $949.3M | $1.12B | $1.39B | $100.2M | $271.7M | $184.6M | $8.3M | — |
| Receivables | $1.0M | $5.7M | $0 | $1.0M | $15.0M | $1.0M | — | $2.8M | $25.0M | — |
| Total current assets | $700.7M | $1.07B | $1.28B | $1.24B | $1.55B | $703.1M | $290.9M | $195.7M | $65.5M | — |
| Property, plant and equipment | $5.2M | $7.0M | $11.5M | $13.4M | $12.7M | $12.3M | $8.5M | $3.6M | $1.3M | — |
| Total assets | $717.9M | $1.09B | $1.30B | $1.27B | $1.58B | $717.4M | $301.6M | $199.3M | $66.8M | — |
| Accounts payable | $24.4M | $13.4M | $17.8M | $5.7M | $31.3M | $7.1M | $4.6M | $2.8M | $596.5K | — |
| Short-term debt | $200.0K | $200.0K | $200.0K | $0 | — | — | — | $154.5K | $159.3K | — |
| Total current liabilities | $142.5M | $229.8M | $257.1M | $295.1M | $261.7M | $49.2M | $32.8M | $23.0M | $17.9M | — |
| Long-term debt | $400.0K | $600.0K | $800.0K | $1.0M | $1.0M | $2.0M | $2.0M | $2.0M | $151.1K | — |
| Total liabilities | $284.0M | $529.7M | $644.6M | $703.9M | $799.9M | $75.2M | $75.0M | $62.6M | $66.6M | — |
| Retained earnings | -$1.61B | -$1.53B | -$1.33B | -$965.4M | -$682.9M | -$491.9M | -$372.6M | -$302.3M | -$62.4M | — |
| Total equity | $433.9M | $561.7M | $660.0M | $564.9M | $781.7M | $642.2M | $226.6M | $136.6M | -$61.2M | -$32.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$273.8M | -$259.3M | -$347.8M | -$273.5M | $559.4M | -$89.7M | -$40.6M | -$16.1M | $5.1M | — |
| Depreciation and amortisation | — | $4.6M | $4.8M | $6.3M | $4.8M | $3.2M | $1.6M | $706.0K | $347.4K | — |
| Stock-based compensation | $44.0M | $88.2M | $71.6M | $75.5M | $57.1M | $30.2M | $20.1M | $11.6M | $245.0K | — |
| Capital expenditure | $1.9M | $1.8M | $2.9M | $6.8M | $4.7M | $6.4M | $6.3M | $2.8M | $1.0M | — |
| Investing cash flow | $407.6M | $34.7M | $203.5M | $242.8M | -$1.31B | $164.3M | -$93.1M | -$179.7M | $20.9M | — |
| Financing cash flow | -$91.4M | $7.9M | $374.7M | $4.7M | $278.6M | $504.6M | $139.7M | $168.1M | -$161.4K | — |
| Buybacks | $91.9M | $0 | $0 | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-028156.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $7.6M | $14.3M | $43.0M | $25.9M | $53.6M | $131.4M | $78.5M | $263.4M | $262.6M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | — | -$24.0M | -$41.5M | -$70.3M | -$119.3M | -$191.0M | -$283.0M | -$367.0M | -$199.0M | -$81.0M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |